Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Identifieur interne : 002B37 ( Main/Exploration ); précédent : 002B36; suivant : 002B38Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Auteurs : Sébastien Benzekry [France] ; Eddy Pasquier [Australie] ; Dominique Barbolosi [France] ; Bruno Lacarelle [France] ; Fabrice Barlési [France] ; Nicolas André [France] ; Joseph Ciccolini [France]Source :
- Seminars in cancer biology [ 1096-3650 ] ; 2015.
Descripteurs français
- KwdFr :
- Administration métronomique, Animaux, Antinéoplasiques (administration et posologie), Humains, Modèles théoriques, Médecine individualisée (), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Tumeurs (anatomopathologie), Tumeurs (métabolisme), Tumeurs (traitement médicamenteux), Tumeurs (étiologie).
- MESH :
- administration et posologie : Antinéoplasiques.
- anatomopathologie : Tumeurs.
- métabolisme : Tumeurs.
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- étiologie : Tumeurs.
- Administration métronomique, Animaux, Humains, Modèles théoriques, Médecine individualisée.
English descriptors
- KwdEn :
- Administration, Metronomic, Animals, Antineoplastic Agents (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Humans, Models, Theoretical, Neoplasms (drug therapy), Neoplasms (etiology), Neoplasms (metabolism), Neoplasms (pathology), Precision Medicine (methods).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents.
- drug therapy : Neoplasms.
- etiology : Neoplasms.
- metabolism : Neoplasms.
- methods : Precision Medicine.
- pathology : Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Administration, Metronomic, Animals, Humans, Models, Theoretical.
Abstract
Oncology has benefited from an increasingly growing number of groundbreaking innovations over the last decade. Targeted therapies, biotherapies, and the most recent immunotherapies all contribute to increase the number of therapeutic options for cancer patients. Consequently, substantial improvements in clinical outcomes for some disease with dismal prognosis such as lung carcinoma or melanoma have been achieved. Of note, the latest innovations in targeted therapies or biotherapies do not preclude the use of standard cytotoxic agents, mostly used in combination. Importantly, and despite the rise of bioguided (a.k.a. precision) medicine, the administration of chemotherapeutic agents still relies on the maximum tolerated drug (MTD) paradigm, a concept inherited from theories conceptualized nearly half a century ago. Alternative dosing schedules such as metronomic regimens, based upon the repeated and regular administration of low doses of chemotherapeutic drugs, and adaptive therapy (i.e. modulating the dose and frequency of cytotoxics administration to control disease progression rather than eradicate it at all cost) have emerged as possible strategies to improve response rates while reducing toxicities. The recent changes in paradigm in the way we theorize cancer biology and evolution, metastatic spreading and tumor ecology, alongside the recent advances in the field of immunotherapy, have considerably strengthened the interest for these alternative approaches. This paper aims at reviewing the recent evolutions in the field of theoretical biology of cancer and computational oncology, with a focus on the consequences these changes have on the way we administer chemotherapy. Here, we advocate for the development of model-guided strategies to refine doses and schedules of chemotherapy administration in order to achieve precision medicine in oncology.
DOI: 10.1016/j.semcancer.2015.09.002
PubMed: 26361213
Affiliations:
- Australie, France
- Aquitaine, Aquitaine-Limousin-Poitou-Charentes, Provence-Alpes-Côte d'Azur
- Bordeaux, Marseille, Talence
- Université de Bordeaux
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002673
- to stream PubMed, to step Curation: 002604
- to stream PubMed, to step Checkpoint: 002604
- to stream Ncbi, to step Merge: 002A50
- to stream Ncbi, to step Curation: 002A50
- to stream Ncbi, to step Checkpoint: 002A50
- to stream Main, to step Merge: 002B37
- to stream Main, to step Curation: 002B37
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.</title><author><name sortKey="Benzekry, Sebastien" sort="Benzekry, Sebastien" uniqKey="Benzekry S" first="Sébastien" last="Benzekry">Sébastien Benzekry</name><affiliation wicri:level="4"><nlm:affiliation>INRIA, Team MONC, Institut de mathématiques de Bordeaux UMR 5251, Université de Bordeaux, Talence, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INRIA, Team MONC, Institut de mathématiques de Bordeaux UMR 5251, Université de Bordeaux, Talence</wicri:regionArea><placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Talence</settlement><settlement type="city" wicri:auto="agglo">Bordeaux</settlement><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><affiliation wicri:level="1"><nlm:affiliation>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Children's Cancer Institute, Randwick, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Children's Cancer Institute, Randwick</wicri:regionArea><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author><author><name sortKey="Barbolosi, Dominique" sort="Barbolosi, Dominique" uniqKey="Barbolosi D" first="Dominique" last="Barbolosi">Dominique Barbolosi</name><affiliation wicri:level="3"><nlm:affiliation>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lacarelle, Bruno" sort="Lacarelle, Bruno" uniqKey="Lacarelle B" first="Bruno" last="Lacarelle">Bruno Lacarelle</name><affiliation wicri:level="3"><nlm:affiliation>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlési">Fabrice Barlési</name><affiliation wicri:level="3"><nlm:affiliation>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Oncologie Multidisciplinaire et d'Innovations Thérapeutiques, Nord University Hospital of Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Oncologie Multidisciplinaire et d'Innovations Thérapeutiques, Nord University Hospital of Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="André">Nicolas André</name><affiliation wicri:level="3"><nlm:affiliation>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Hematologie et Oncologie Pediatrique, La Timone Hospital, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Hematologie et Oncologie Pediatrique, La Timone Hospital, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Ciccolini, Joseph" sort="Ciccolini, Joseph" uniqKey="Ciccolini J" first="Joseph" last="Ciccolini">Joseph Ciccolini</name><affiliation wicri:level="3"><nlm:affiliation>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France. Electronic address: joseph.ciccolini@univ-amu.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26361213</idno><idno type="pmid">26361213</idno><idno type="doi">10.1016/j.semcancer.2015.09.002</idno><idno type="wicri:Area/PubMed/Corpus">002673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002673</idno><idno type="wicri:Area/PubMed/Curation">002604</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002604</idno><idno type="wicri:Area/PubMed/Checkpoint">002604</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002604</idno><idno type="wicri:Area/Ncbi/Merge">002A50</idno><idno type="wicri:Area/Ncbi/Curation">002A50</idno><idno type="wicri:Area/Ncbi/Checkpoint">002A50</idno><idno type="wicri:Area/Main/Merge">002B37</idno><idno type="wicri:Area/Main/Curation">002B37</idno><idno type="wicri:Area/Main/Exploration">002B37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.</title><author><name sortKey="Benzekry, Sebastien" sort="Benzekry, Sebastien" uniqKey="Benzekry S" first="Sébastien" last="Benzekry">Sébastien Benzekry</name><affiliation wicri:level="4"><nlm:affiliation>INRIA, Team MONC, Institut de mathématiques de Bordeaux UMR 5251, Université de Bordeaux, Talence, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INRIA, Team MONC, Institut de mathématiques de Bordeaux UMR 5251, Université de Bordeaux, Talence</wicri:regionArea><placeName><region type="region" nuts="2">Aquitaine-Limousin-Poitou-Charentes</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Talence</settlement><settlement type="city" wicri:auto="agglo">Bordeaux</settlement><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName></affiliation></author><author><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name><affiliation wicri:level="1"><nlm:affiliation>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Children's Cancer Institute, Randwick, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Children's Cancer Institute, Randwick</wicri:regionArea><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author><author><name sortKey="Barbolosi, Dominique" sort="Barbolosi, Dominique" uniqKey="Barbolosi D" first="Dominique" last="Barbolosi">Dominique Barbolosi</name><affiliation wicri:level="3"><nlm:affiliation>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lacarelle, Bruno" sort="Lacarelle, Bruno" uniqKey="Lacarelle B" first="Bruno" last="Lacarelle">Bruno Lacarelle</name><affiliation wicri:level="3"><nlm:affiliation>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlési">Fabrice Barlési</name><affiliation wicri:level="3"><nlm:affiliation>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Oncologie Multidisciplinaire et d'Innovations Thérapeutiques, Nord University Hospital of Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Oncologie Multidisciplinaire et d'Innovations Thérapeutiques, Nord University Hospital of Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="André">Nicolas André</name><affiliation wicri:level="3"><nlm:affiliation>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Hematologie et Oncologie Pediatrique, La Timone Hospital, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Service d'Hematologie et Oncologie Pediatrique, La Timone Hospital, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Ciccolini, Joseph" sort="Ciccolini, Joseph" uniqKey="Ciccolini J" first="Joseph" last="Ciccolini">Joseph Ciccolini</name><affiliation wicri:level="3"><nlm:affiliation>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille, France. Electronic address: joseph.ciccolini@univ-amu.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metronomics Global Health Initiative, Marseille, France; INSERM UMR S_911 CRO2, Aix Marseille Univ., Marseille, France; Clinical Pharmacokinetics, La Timone University Hospital of Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author></analytic><series><title level="j">Seminars in cancer biology</title><idno type="eISSN">1096-3650</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Metronomic</term><term>Animals</term><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Humans</term><term>Models, Theoretical</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (etiology)</term><term>Neoplasms (metabolism)</term><term>Neoplasms (pathology)</term><term>Precision Medicine (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration métronomique</term><term>Animaux</term><term>Antinéoplasiques (administration et posologie)</term><term>Humains</term><term>Modèles théoriques</term><term>Médecine individualisée ()</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Tumeurs (anatomopathologie)</term><term>Tumeurs (métabolisme)</term><term>Tumeurs (traitement médicamenteux)</term><term>Tumeurs (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Precision Medicine</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Metronomic</term><term>Animals</term><term>Humans</term><term>Models, Theoretical</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration métronomique</term><term>Animaux</term><term>Humains</term><term>Modèles théoriques</term><term>Médecine individualisée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oncology has benefited from an increasingly growing number of groundbreaking innovations over the last decade. Targeted therapies, biotherapies, and the most recent immunotherapies all contribute to increase the number of therapeutic options for cancer patients. Consequently, substantial improvements in clinical outcomes for some disease with dismal prognosis such as lung carcinoma or melanoma have been achieved. Of note, the latest innovations in targeted therapies or biotherapies do not preclude the use of standard cytotoxic agents, mostly used in combination. Importantly, and despite the rise of bioguided (a.k.a. precision) medicine, the administration of chemotherapeutic agents still relies on the maximum tolerated drug (MTD) paradigm, a concept inherited from theories conceptualized nearly half a century ago. Alternative dosing schedules such as metronomic regimens, based upon the repeated and regular administration of low doses of chemotherapeutic drugs, and adaptive therapy (i.e. modulating the dose and frequency of cytotoxics administration to control disease progression rather than eradicate it at all cost) have emerged as possible strategies to improve response rates while reducing toxicities. The recent changes in paradigm in the way we theorize cancer biology and evolution, metastatic spreading and tumor ecology, alongside the recent advances in the field of immunotherapy, have considerably strengthened the interest for these alternative approaches. This paper aims at reviewing the recent evolutions in the field of theoretical biology of cancer and computational oncology, with a focus on the consequences these changes have on the way we administer chemotherapy. Here, we advocate for the development of model-guided strategies to refine doses and schedules of chemotherapy administration in order to achieve precision medicine in oncology.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Aquitaine</li><li>Aquitaine-Limousin-Poitou-Charentes</li><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Bordeaux</li><li>Marseille</li><li>Talence</li></settlement><orgName><li>Université de Bordeaux</li></orgName></list><tree><country name="France"><region name="Aquitaine-Limousin-Poitou-Charentes"><name sortKey="Benzekry, Sebastien" sort="Benzekry, Sebastien" uniqKey="Benzekry S" first="Sébastien" last="Benzekry">Sébastien Benzekry</name></region><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="André">Nicolas André</name><name sortKey="Barbolosi, Dominique" sort="Barbolosi, Dominique" uniqKey="Barbolosi D" first="Dominique" last="Barbolosi">Dominique Barbolosi</name><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlési">Fabrice Barlési</name><name sortKey="Ciccolini, Joseph" sort="Ciccolini, Joseph" uniqKey="Ciccolini J" first="Joseph" last="Ciccolini">Joseph Ciccolini</name><name sortKey="Lacarelle, Bruno" sort="Lacarelle, Bruno" uniqKey="Lacarelle B" first="Bruno" last="Lacarelle">Bruno Lacarelle</name></country><country name="Australie"><noRegion><name sortKey="Pasquier, Eddy" sort="Pasquier, Eddy" uniqKey="Pasquier E" first="Eddy" last="Pasquier">Eddy Pasquier</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26361213
|texte= Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26361213" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |